Funders · Entity Annotation Prototype (beta)

7articles mentioning funders

8funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: AstraZeneca ×

AstraZeneca

This funder is selected. Its supporting articles are shown below.

AstraZeneca7

Articles mentioning AstraZeneca

7 articles · page 1 of 1

718 Global quantitative patient chart review of multidisciplinary team (MDT) care and treatment use in early-stage non-small-cell lung cancer (NSCLC)

jitc · abstract · 2025-11-04 · 2 matching annotations

96.2%

AstraZeneca neoadjuvant treatment chemoradiotherapy stage I-IIIB NSCLC consolidation therapy adjuvant therapy neoadjuvant therapy surgery NSCLC

…us community settings.Acknowledgements This study was funded by AstraZeneca. Medical writing support for the development of this abstract, …

PO:11:300 Evaluating DORIS remission attainment with anifrolumab in immunosuppressant- and biologic-naïve patients with SLE: design of SUNFLOWER, a phase 3b prospective study

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

93.8%

AstraZeneca Avalere Health SLE anifrolumab DORIS SUNFLOWER

…. ARD. 2025;84:168–9. Vital. ARD. 2025;84:1284–5.Study sponsor: AstraZeneca. Medical writing: Adam Creasey, MSc; Mark Lawrence, PhD (Avaler…

PT7:02 Discordance between SLEDAI-2K and BILAG-2004 disease activity classification leads to divergent treatment decisions under EULAR 2023 recommendations: a post-hoc analysis of anifrolumab trials

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

87.3%

AstraZeneca Vivli Vivli,Inc SLE lupus SLE-DAS anifrolumab BILAG-2004 EQ-5D SLEDAI-2K

…lication is based on research using data from data contributors AstraZeneca that has been made available through Vivli,Inc. Vivli has not c…

S13:01 The novel SLE-DAS responder index aligns clinical endpoints with patient experience and outperforms BICLA and SRI-4 in capturing HRQoL: post-hoc analysis in the MUSE, TULIP-1 and TULIP-2 trials

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

85.5%

AstraZeneca Vivli Vivli, Inc SLE SLE-DAS anifrolumab MSDA

…lication is based on research using data from data contributors AstraZeneca that has been made available through Vivli, Inc. Vivli has not …

518 Capivasertib, an AKT inhibitor, remodels the tumor microenvironment to synergize with combination therapy of olaparib and durvalumab in susceptible advanced/metastatic solid cancers

jitc · abstract · 2025-11-04 · 1 matching annotations

85.2%

AstraZeneca durvalumab capivasertib Durva olaparib Ola Cap relapse/refractory solid cancers

…ing macrophages and stromal cells are underway.Acknowledgements AstraZeneca’s support is gratefully acknowledgedTrial Registration NCT03772…

P200 Real World Experience; an interim analysis of effectiveness of tezepelumab in patients with severe uncontrolled asthma across the UK

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

98.6%

AstraZeneca tezepelumab SuA maintenance treatment patient access programme

…will include approximately 350 patients.Sponsored and funded by AstraZeneca…

P66 Improving asthma outcomes in Lancashire and South Cumbria (L&SC) through SABA reduction and MART implementation with SENTINEL Plus

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

95.5%

AstraZeneca NHS asthma SENTINEL Plus SABA-only SABA Interface Pharmacy Services

…arbon footprint.Strategy for change L&SC ICB joint working with AstraZeneca using SENTINEL Plus, a quality improvement programme that aims …

Browse funders

AstraZeneca

Articles mentioning AstraZeneca

718 Global quantitative patient chart review of multidisciplinary team (MDT) care and treatment use in early-stage non-small-cell lung cancer (NSCLC)

PO:11:300 Evaluating DORIS remission attainment with anifrolumab in immunosuppressant- and biologic-naïve patients with SLE: design of SUNFLOWER, a phase 3b prospective study

PT7:02 Discordance between SLEDAI-2K and BILAG-2004 disease activity classification leads to divergent treatment decisions under EULAR 2023 recommendations: a post-hoc analysis of anifrolumab trials

S13:01 The novel SLE-DAS responder index aligns clinical endpoints with patient experience and outperforms BICLA and SRI-4 in capturing HRQoL: post-hoc analysis in the MUSE, TULIP-1 and TULIP-2 trials

518 Capivasertib, an AKT inhibitor, remodels the tumor microenvironment to synergize with combination therapy of olaparib and durvalumab in susceptible advanced/metastatic solid cancers

P200 Real World Experience; an interim analysis of effectiveness of tezepelumab in patients with severe uncontrolled asthma across the UK

P66 Improving asthma outcomes in Lancashire and South Cumbria (L&SC) through SABA reduction and MART implementation with SENTINEL Plus